Completed PHASE2 INTERVENTIONAL NCT00004081

Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer

A Phase II Trial of Weekly, Low-Dose Docetaxel (Taxotere) in Patients With Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Serous Cancer

Sponsor: Beth Israel Deaconess Medical Center

Conditions Ovarian Cancer Peritoneal Cavity Cancer

Interventions docetaxel

Updated 5 times since 2017 Last updated: Aug 9, 2012 Started: Jul 31, 1999 Primary completion: Jan 31, 2002 Completion: Mar 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ovarian Cancer and Peritoneal Cavity Cancer, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 5 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beth Israel Deaconess Medical Center

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States